ST Innovative Diagnostics developed a novel blood-based malignancy monitoring test, based on research from Rabin Medical Center and Tel Aviv University. The company's proprietary technology & kit, measures Fibrinogen Like Protein 2 (FGL2) activity in platelets, enabling non-invasive disease monitoring and relapse prediction across multiple malignancies. POC Clinical studies have shown high correlation with PET/CT imaging in Non-Hodgkin's Lymphoma, Prostate Cancer, and Cutaneous T-Cell Lymphoma. The technology shows promise for early detection of treatment resistance in NHL patients, facilitating timely transition to second-line therapies and preventing T-cell exhaustion and is planned to expand to solid tumor monitoring & diagnosis, including Metastatic Colorectal and Pancreatic Cancers.